Cardiac Manifestations of Systemic Lupus Erythematosus

Rheumatic Disease Clinics of North America

Volumn 40, Issue 1, 2014, Pages 51-60

  Miner, Jonathan J ^a   Kim, Alfred H J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Congenital heart block; Coronary artery disease; Libman Sacks; Myocarditis; Neonatal lupus; Pericarditis; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; ATORVASTATIN; AZATHIOPRINE; BELIMUMAB; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; RO ANTIBODY; STEROID;

AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTERITIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONGENITAL HEART BLOCK; CORONARY ARTERITIS; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPNEA; ECG ABNORMALITY; ENDOCARDITIS; HEART INFARCTION; HEART TAMPONADE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; MITRAL VALVE REGURGITATION; MYOCARDITIS; NEONATAL LUPUS; NEPHRITIS; NONHUMAN; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERICARDITIS; PLEURISY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THORAX PAIN; TRANSCATHETER AORTIC VALVE IMPLANTATION; WEIGHT GAIN;

CONGENITAL HEART BLOCK; CORONARY ARTERY DISEASE; LIBMAN-SACKS; MYOCARDITIS; NEONATAL LUPUS; PERICARDITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

CARDIOMYOPATHIES; CORONARY ARTERY DISEASE; HEART BLOCK; HEART DISEASES; HEART VALVE DISEASES; HUMANS; INFANT, NEWBORN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MYOCARDITIS; PERICARDITIS;

EID: 84888168491     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2013.10.003     Document Type: Review

References (70)

1. Scott J.S., Maddison P.J., Taylor P.V., et al. Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block. NEngl J Med 1983, 309:209-212.
2. Lee L.A. Transient autoimmunity related to maternal autoantibodies: neonatal lupus. Autoimmun Rev 2005, 4:207-213.
3. Saleeb S., Copel J., Friedman D., et al. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus. Arthritis Rheum 1999, 42:2335-2345.
4. Buyon J.P., Hiebert R., Copel J., et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. JAm Coll Cardiol 1998, 31:1658-1666.
5. Jayaprasad N., Johnson F., Venugopal K. Congenital complete heart block and maternal connective tissue disease. Int J Cardiol 2006, 112:153-158.
6. Friedman D., Rupel A., Buyon J. Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep 2007, 9:101-108.
7. Lazzerini P.E., Acampa M., Guideri F., et al. Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA- positive connective tissue diseases. Arthritis Rheum 2004, 50:1248-1252.
8. Bourré-Tessier J., Clarke A.E., Huynh T., et al. Prolonged corrected QT interval in anti-Ro/SSA-positive adults with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011, 63:1031-1037.
9. Lazzerini P.E., Capecchi P.L., Guideri F., et al. Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro/SSA and connective tissue disease. Am J Cardiol 2007, 100:1029-1034.
10. Buyon J., Clancy R. Neonatal lupus: review of proposed pathogenesis and clinical data from the US-based Research Registry for Neonatal Lupus. Autoimmunity 2003, 36:41-50.
11. Litsey S.E., Noonan J.A., O'Connor W.N., et al. Maternal connective tissue disease and congenital heart block. NEngl J Med 1985, 312:98-100.
12. Brucato A., Frassi M., Franceschini F., et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001, 44:1832-1835.
13. Julkunen H., Eronen M. The rate of recurrence of isolated congenital heart block: a population-based study. Arthritis Rheum 2001, 44:487-488.
14. Cooley H., Keech C., Melny B., et al. Monozygotic twins discordant for congenital complete heart block. Arthritis Rheum 1997, 40:381-384.
15. Pisoni C.N., Brucato A., Ruffatti A., et al. Failure of intravenous immunoglobulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 2010, 62:1147-1152.
16. Hutter D., Silverman E.D., Jaeggi E.T. The benefits of transplacental treatment of isolated congenital complete heart block associated with maternal anti-Ro/SSA antibodies: a review. Scand J Immunol 2010, 72:235-241.
17. Geggel R., Tucker L., Szer I. Postnatal progression from second- to third-degree heart block in neonatal lupus syndrome. JPediatr 1988, 113:1049-1052.
18. Izmirly P.M., Costedoat-Chalumeau N., Pisoni C.N., et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012, 126:76-82.
19. Moder K.G., Miller T.D., Tazelaar H.D. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc 1999, 74:275-284.
20. Galve E., Candell-Riera J., Pigrau C., et al. Prevalence, morphologic types, and evolution of cardiac valvular disease in systemic lupus erythematosus. NEngl J Med 1988, 319:817-823.
21. Starkey R.H., Hahn B.H. Rapid development of constrictive pericarditis in a patient with systemic lupus erythematosus. Chest 1973, 63:448-450.
22. Jacobson E., Reza M. Constrictive pericarditis in systemic lupus erythematosus. Demonstration of immunoglobulins in the pericardium. Arthritis Rheum 1978, 21:972-974.
23. Cauduro S.A., Moder K.G., Tsang T.S., et al. Clinical and echocardiographic characteristics of hemodynamically significant pericardial effusions in patients with systemic lupus erythematosus. Am J Cardiol 2003, 92:1370-1372.
24. Rosenbaum E., Krebs E., Cohen M., et al. The spectrum of clinical manifestations, outcome and treatment of pericardial tamponade in patients with systemic lupus erythematosus: a retrospective study and literature review. Lupus 2009, 18:608-612.
25. Kahl L. The spectrum of pericardial tamponade in systemic lupus erythematosus. Report of ten patients. Arthritis Rheum 1992, 35:1343-1349.
26. Carroll N., Barrett J. Systemic lupus erythematosus presenting with cardiac tamponade. Br Heart J 1984, 51:452-453.
27. Arabi M.T., Malek E.M., Fares M.H., et al. Cardiac tamponade as the first manifestation of systemic lupus erythematosus in children. BMJ Case Rep 2012, [Epub ahead print].
28. Lindop R., Arentz G., Thurgood L.A., et al. Pathogenicity and proteomic signatures of autoantibodies to Ro and La. Immunol Cell Biol 2012, 90:304-309.
29. Quismorio F.P. Immune complexes in the pericardial fluid in systemic lupus erythematosus. Arch Intern Med 1980, 140:112-114.
30. Suarez-Almazor M., Gonzalez-Lopez L., Gamez-Nava J., et al. Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians. JRheumatol 1998, 25:1980-1985.
31. Imazio M., Spodick D.H., Brucato A., et al. Controversial issues in the management of pericardial diseases. Circulation 2010, 121:916-928.
32. Apte M., McGwin G., Vilá L.M., LUMINA Study Group, et al. Associated factors and impact of myocarditis in patients with SLE from LUMINA, a multiethnic US cohort. Rheumatology 2008, 47:362-367.
33. Doherty N., Siegel R. Cardiovascular manifestations of systemic lupus erythematosus. Am Heart J 1985, 110:1257-1265.
34. Jain D., Halushka M.K. Cardiac pathology of systemic lupus erythematosus. JClin Pathol 2009, 62:584-592.
35. Saremi F., Ashikyan O., Saggar R., et al. Utility of cardiac MRI for diagnosis and post-treatment follow-up of lupus myocarditis. Int J Cardiovasc Imaging 2007, 23:347-352.
36. Mavrogeni S., Bratis K., Markussis V., et al. The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis. Lupus 2013, 22:34-43.
37. Fairfax M., Osborn T., Williams G., et al. Endomyocardial biopsy in patients with systemic lupus erythematosus. JRheumatol 1988, 15:593-596.
38. Kavanagh D., Spitzer D., Kothari P., et al. New roles for the major human 3'- 5' exonuclease TREX1 in human disease. Cell Cycle 2008, 7:1718-1725.
39. Lee-Kirsch M.A., Gong M., Chowdhury D., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 2007, 39:1065-1067.
40. Morita M., Stamp G., Robins P., et al. Gene-targeted mice lacking the Trex1 (DNase III) 3'→5' DNA exonuclease develop inflammatory myocarditis. Mol Cell Biol 2004, 24:6719-6727.
41. Rubin L.A., Urowitz M.B., Gladman D.D. Mortality in systemic lupus erythematosus: the bimodal pattern revisited. QJM 1985, 55:87-98.
42. Sumpter M.D., Tatro L.S., Stoecker W.V., et al. Evidence for risk of cardiomyopathy with hydroxychloroquine. Lupus 2012, 21:1594-1596.
43. Vaccaro F., Caccavo D., Roumpedaki E., et al. Dilated cardiomyopathy due to thrombotic microangiopathy as the only manifestation of antiphospholipid syndrome: a case report. Int J Immunopathol Pharmacol 2008, 21:237-241.
44. Abu-Shakra M., Urowitz M., Gladman D., et al. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. JRheumatol 1995, 22:1259-1264.
45. Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:338-346.
46. Heibel R.H., O'Toole J.D., Curtiss E.I., et al. Coronary arteritis in systemic lupus erythematosus. Chest 1976, 69:700-703.
47. Bonfiglio T., Botti R., Hagstrom J. Coronary arteritis, occlusion, and myocardial infarction due to lupus erythematosus. Am Heart J 1972, 83:153-158.
48. Artenjak A., Lakota K., Frank M., et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev 2012, 11:873-882.
49. Sherer Y., Gerli R., Gilburd B., et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 2007, 16:259-264.
50. Ishikawa S., Segar W.E., Gilbert E.F., et al. Myocardial infarct in a child with systemic lupus erythematosus. Am J Dis Child 1978, 132:696-699.
51. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol 1997, 145:408-415.
52. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEngl J Med 2002, 347:1557-1565.
53. Ettinger W.H., Goldberg A.P., Applebaum-Bowden D., et al. Dyslipoproteinemia in systemic lupus erythematosus: effect of corticosteroids. Am J Med 1987, 83:503-508.
54. Petri M., Lakatta C., Magder L., et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254-259.
55. Karp I., Abrahamowicz M., Fortin P.R., et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus?. Arthritis Care Res (Hoboken) 2008, 59:169-175.
56. Salmon J.E., Roman M.J. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med 2008, 121:S3-S8.
57. Haque S., Bruce I. Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease. Nat Clin Pract Cardiovasc Med 2005, 2:423-430.
58. Petri M.A. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996, 5(Suppl 1):S16-S22.
59. Petri M.A., Kiani A.N., Post W., et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011, 70:760-765.
60. Moreno P.R., Lodder R.A., Purushothaman K.R., et al. Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near- infrared spectroscopy. Circulation 2002, 105:923-927.
61. Anania C., Gustafsson T., Hua X., et al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R214.
62. Boyle J.J. Association of coronary plaque rupture and atherosclerotic inflammation. JPathol 1997, 181:93-99.
63. Libman E., Sacks B. Ahitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 1924, 33:701-707.
64. Moyssakis I., Tektonidou M.G., Vasilliou V.A., et al. Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution. Am J Med 2007, 120:636-642.
65. Roldan C.A., Qualls C.R., Sopko K.S., et al. Transthoracic versus transesophageal echocardiography for detection of Libman-Sacks endocarditis: a randomized controlled study. JRheumatol 2008, 35:224-229.
66. Straaton K., Chatham W., Reveille J., et al. Clinically significant valvular heart disease in systemic lupus erythematosus. Am J Med 1988, 85:645-650.
67. Paget S., Bulkley B., Grauer L., et al. Mitral valve disease of systemic lupus erythematosus. A cause of severe congestive heart failure reversed by valve replacement. Am J Med 1975, 59:134-139.
68. Ziporen L., Goldberg I., Arad M., et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 1996, 5:196-205.
69. Ashikhmina E.A., Schaff H.V., Dearani J.A., et al. Aortic valve replacement in the elderly: determinants of late outcome. Circulation 2011, 124:1070-1078.
70. Bert J.S., Abdullah M., Dahle T.G., et al. Transcatheter aortic valve replacement for advanced valvular disease in active SLE and APS. Lupus 2013, 22:1046-1049.